James Gallo, PhD, received a 2015 award from the American Society for Clinical Pharmacology and Therapeutics (ASCPT) for two research articles, one commentary and one podcast, that his group published in CPT: Pharmacometrics and Systems Pharmacology (CPT:PSP), an online, sibling journal to the highly regarded Clinical Pharmacology & Therapeutics. Both journals are published by ASCPT. In addition to recognizing quality research, the award honors Dr. Gallo’s review of multiple papers for the journal, and his service on the editorial board.
ASCPT is invested in better understanding and utilizing existing drug therapies, and in establishing safer and more effective treatments. Founded in 1900, their mission is to advance the science and practice of clinical pharmacology and translational medicine for all. CPT:PSP is a cross-disciplinary journal that publishes significant findings in quantitative methods being used in human physiology, pharmacology, and therapeutics.
Dr. Gallo’s podcast, “Systems Pharmacology Approaches in Oncology” aired in August 2014 and can be viewed in the Wiley Online Library archives. The commentary was on this topic as well, and on March 3, 2015, Dr. Gallo presented his findings at the “Clinical Pharmacology: Toward a Global Agenda Conference,” co-Sponsored by ASCPT and the International Consortium for the Innovation and Quality in Pharmaceutical Development. The year before, Dr. Gallo and Victor Levin M.D. initiated the Organizing and Scientific Committee for the “CNS Anticancer Drug Discovery/Development Conference.”
Dr. Gallo is Professor of Pharmacology and Systems Therapeutics in the Biophysics and Systems Pharmacology training area of the Graduate School of Biomedicine. He is the Principal investigator of the Gallo Laboratory, focused on pharmacokinetic and pharmacodynamic (PK/PD) directed brain tumor chemotherapy. He and his team have incorporated systems based methods to derive cell-type specific PK/PD and enhanced PD models that link information at the cellular and molecular levels. Dr. Gallo continues to investigate potential anticancer pharmaceuticals, oncometabolites, epigenetic modulators, and tumor heterogeneity.